Literature DB >> 26359934

Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors.

Tiffany C L Wong1, James Y Y Fung2, Kenneth S H Chok1, Tan To Cheung1, Albert C Y Chan1, William W Sharr1, Wing Chiu Dai1, See Ching Chan1, Chung Mau Lo1.   

Abstract

Liver grafts with macrovesicular steatosis of > 60% are considered unsuitable for deceased donor liver transplantation (DDLT) because of the unacceptably high risk of primary nonfunction (PNF) and graft loss. This study reports our experience in using such grafts from brain-dead donors. Prospectively collected data of DDLT recipient outcomes from 1991 to 2013 were retrospectively analyzed. Macrovesicular steatosis > 60% at postperfusion graft biopsy was defined as severe steatosis. In total, 373 patients underwent DDLT. Nineteen patients received severely steatotic grafts (ie, macrovesicular steatosis > 60%), and 354 patients had grafts with ≤ 60% steatosis (control group). Baseline demographics were comparable except that recipient age was older in the severe steatosis group (51 versus 55 years; P = 0.03). Median Model for End-Stage Liver Disease (MELD) score was 20 in the severe steatosis group and 22 in the control group. Cold ischemia time (CIT) was 384 minutes in the severe steatosis group and 397.5 minutes in the control group (P = 0.66). The 2 groups were similar in duration of stay in the hospital and in the intensive care unit. Risk of early allograft dysfunction (0/19 [0%] versus 1/354 [0.3%]; P>0.99) and 30-day mortality (0/19 [0%] versus 11/354 [3.1%]; P = 0.93) were also similar between groups. No patient developed PNF. The 1-year and 3-year overall survival rates in the severe steatosis group were both 94.7%. The corresponding rates in the control group were 91.8% and 85.8% (P = 0.55). The use of severely steatotic liver grafts from low-risk donors was safe, and excellent outcomes were achieved; however, these grafts should be used with caution, especially in patients with high MELD score. Keeping a short CIT was crucial for the successful use of such grafts in liver transplantation.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 26359934     DOI: 10.1002/lt.24335

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  19 in total

1.  Resolution of donor non-alcoholic fatty liver disease following liver transplantation.

Authors:  Andrew D Posner; Samuel T Sultan; Norann A Zaghloul; William S Twaddell; David A Bruno; Steven I Hanish; William R Hutson; Laci Hebert; Rolf N Barth; John C LaMattina
Journal:  Clin Transplant       Date:  2017-07-13       Impact factor: 2.863

Review 2.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

3.  Berberine protects steatotic donor undergoing liver transplantation via inhibiting endoplasmic reticulum stress-mediated reticulophagy.

Authors:  Nan Zhang; Mingwei Sheng; Man Wu; Xinyue Zhang; Yijie Ding; Yuanbang Lin; Wenli Yu; Shusen Wang; Hongyin Du
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-25

4.  Clear mortality gap caused by graft macrosteatosis in Chinese patients after cadaveric liver transplantation.

Authors:  Zhengtao Liu; Wenchao Wang; Li Zhuang; Jingfeng Liu; Shuping Que; Dan Zhu; Linfang Dong; Jian Yu; Lin Zhou; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

5.  Metabonomic Profile of Macrosteatotic Allografts for Orthotopic Liver Transplantation in Patients With Initial Poor Function: Mechanistic Investigation and Prognostic Prediction.

Authors:  Zhengtao Liu; Hai Zhu; Wenchao Wang; Jun Xu; Shuping Que; Li Zhuang; Junjie Qian; Shuai Wang; Jian Yu; Feng Zhang; Shengyong Yin; Haiyang Xie; Lin Zhou; Lei Geng; Shusen Zheng
Journal:  Front Cell Dev Biol       Date:  2020-08-28

Review 6.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

7.  Effect of Donor Hepatic Steatosis on Ischemia Reperfusion Injury in Liver Transplant Recipient.

Authors:  Prafulla V Jadhav; Sunil Raviraj Kothakota; Madhu Sasidharan; Harish Kareem; Ajith K Nair
Journal:  J Clin Exp Hepatol       Date:  2019-07-12

8.  Impact of Graft Steatosis on Postoperative Complications after Liver Transplantation.

Authors:  Emad Ali Ahmed; Ashraf Mohammad El-Badry; Federico Mocchegiani; Roberto Montalti; Asem Elsani Ali Hassan; Alaa Ahmed Redwan; Marco Vivarelli
Journal:  Surg J (N Y)       Date:  2018-10-18

Review 9.  Complement Activation in Liver Transplantation: Role of Donor Macrosteatosis and Implications in Delayed Graft Function.

Authors:  Kelley Núñez; Paul Thevenot; Abeer Alfadhli; Ari Cohen
Journal:  Int J Mol Sci       Date:  2018-06-13       Impact factor: 5.923

10.  Outcomes of Adult Liver Transplantation from Donation After Brain Death Followed by Circulatory Death in China.

Authors:  Jiabin Zhang; Hui Ren; Yanling Sun; Zhijie Li; Hongbo Wang; Zhenwen Liu; Shaotang Zhou
Journal:  Ann Transplant       Date:  2018-05-01       Impact factor: 1.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.